IS8266A - Breytt mennsk IGF-1R mótefni - Google Patents

Breytt mennsk IGF-1R mótefni

Info

Publication number
IS8266A
IS8266A IS8266A IS8266A IS8266A IS 8266 A IS8266 A IS 8266A IS 8266 A IS8266 A IS 8266A IS 8266 A IS8266 A IS 8266A IS 8266 A IS8266 A IS 8266A
Authority
IS
Iceland
Prior art keywords
antibody
modified human
human igf
igf
modified
Prior art date
Application number
IS8266A
Other languages
English (en)
Inventor
David Cohen Bruce
Bedian Vahe
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS8266A publication Critical patent/IS8266A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS8266A 2003-08-13 2006-01-26 Breytt mennsk IGF-1R mótefni IS8266A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49520003P 2003-08-13 2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en) 2003-08-13 2004-08-03 Modified human igf-1r antibodies

Publications (1)

Publication Number Publication Date
IS8266A true IS8266A (is) 2006-01-26

Family

ID=34193291

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8266A IS8266A (is) 2003-08-13 2006-01-26 Breytt mennsk IGF-1R mótefni

Country Status (37)

Country Link
US (2) US7371378B2 (is)
EP (1) EP1656391B1 (is)
JP (1) JP4638870B2 (is)
KR (1) KR100825156B1 (is)
CN (1) CN1835975B (is)
AP (1) AP2006003510A0 (is)
AR (1) AR045247A1 (is)
AT (1) ATE484525T1 (is)
AU (1) AU2004265152A1 (is)
BR (1) BRPI0413466A (is)
CA (1) CA2535071A1 (is)
CL (1) CL2004002035A1 (is)
CR (1) CR8233A (is)
DE (1) DE602004029581D1 (is)
DK (1) DK1656391T3 (is)
EA (1) EA200600234A1 (is)
EC (1) ECSP066359A (is)
ES (1) ES2351395T3 (is)
GT (1) GT200400158A (is)
IL (1) IL173273A (is)
IS (1) IS8266A (is)
MA (1) MA27988A1 (is)
MX (1) MXPA06001634A (is)
NL (1) NL1026829C2 (is)
NO (1) NO20060542L (is)
OA (1) OA13234A (is)
PA (1) PA8608801A1 (is)
PE (1) PE20050339A1 (is)
PL (1) PL1656391T3 (is)
PT (1) PT1656391E (is)
RS (1) RS20060099A (is)
TN (1) TNSN06050A1 (is)
TW (1) TWI294915B (is)
UA (1) UA85058C2 (is)
UY (1) UY28464A1 (is)
WO (1) WO2005016967A2 (is)
ZA (1) ZA200601231B (is)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
EP1622942B1 (en) * 2003-05-01 2014-11-19 ImClone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
MX2007000610A (es) 2004-07-16 2007-03-07 Pfizer Prod Inc Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
WO2006060419A2 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) * 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
EP1896505A2 (en) * 2005-06-15 2008-03-12 Schering Corporation Anti-igf1r antibody formulations
EP2100614B8 (en) * 2005-06-17 2013-11-20 ImClone LLC Antibody against PDGFR-alpha for use in the treatment of tumours
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
UA95945C2 (ru) * 2006-02-03 2011-09-26 Имклоун Ллк Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
DK2027470T3 (da) 2006-06-02 2013-02-04 Pfizer Prod Inc Analyse for cirkulerende tumorceller
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CA2679548C (en) * 2007-03-02 2015-01-27 Amgen Inc. Methods and compositions for treating tumor diseases
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
KR20090113340A (ko) * 2007-03-22 2009-10-29 임클론 엘엘씨 안정한 항체 제제
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
MX2010010480A (es) * 2008-03-25 2010-10-15 Schering Corp Metodos de tratamiento o prevencion del cancer colorrectal.
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
JP2012508022A (ja) * 2008-11-06 2012-04-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 減少した免疫原性を有する操作された抗体および作製方法
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ,エルエルシー 併用抗癌治療
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以dll4拮抗劑與化學治療劑治療癌症之方法
SG10201510640QA (en) 2009-10-26 2016-01-28 Hoffmann La Roche Method For The Production Of A Glycosylated Immunoglobulin
WO2011053779A2 (en) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
AU2011277999A1 (en) 2010-07-12 2013-01-10 Covx Technologies Ireland Limited Multifunctional Antibody Conjugates
EP2671082B1 (en) 2011-02-02 2020-01-15 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
US20130323234A1 (en) * 2012-01-09 2013-12-05 Covx Technologies Ireland Limited Mutant antibodies and conjugation thereof
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
SG11201502937PA (en) * 2012-11-06 2015-06-29 Medimmune Llc COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES
TWI747803B (zh) 2013-04-29 2021-12-01 瑞士商赫孚孟拉羅股份公司 人類結合fcrn之經修飾抗體及使用方法
MX2015015060A (es) 2013-04-29 2016-02-25 Hoffmann La Roche Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso.
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用
CA2932364A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
EP3484925B1 (en) * 2017-07-27 2020-05-27 iTeos Therapeutics SA Anti-tigit antibodies
WO2019117685A2 (ko) 2017-12-14 2019-06-20 에이비엘바이오 주식회사 항-igf1r 항체 및 그 용도

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9203459D0 (en) * 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP3053222B2 (ja) 1995-04-20 2000-06-19 ファイザー・インコーポレーテッド Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
IL118626A0 (en) 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
YU1899A (sh) 1996-07-18 2000-03-21 Pfizer Inc. Inhibitori matričnih metaloproteaza na bazi fosfinata
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
NZ596723A (en) 1999-03-25 2013-07-26 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
ES1042735Y (es) 1999-04-07 2000-02-16 Martinez Fernando Martinez Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de) 2000-07-12 2003-07-31 Karlsruhe Forschzent HTS-Kryomagnet und Aufmagnetisierungsverfahren
HUP0302525A2 (hu) 2001-01-05 2003-10-28 Abgenix, Inc. Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
EP1361893B1 (en) 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
CN100410275C (zh) 2002-01-18 2008-08-13 皮埃尔法布雷医药公司 新的抗igf-ir抗体及其应用
EP1505075B1 (en) 2002-04-30 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Antibody to human insulin-like growth factor
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006517581A (ja) 2003-02-13 2006-07-27 ファイザー・プロダクツ・インク 抗インスリン様増殖因子i受容体抗体の使用
BRPI0408317A (pt) 2003-03-14 2006-03-07 Pharmacia Corp anticorpos do receptor de igf-i para o tratamento de cáncer
ATE549359T1 (de) 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.

Also Published As

Publication number Publication date
WO2005016967A3 (en) 2005-04-14
AU2004265152A1 (en) 2005-02-24
CN1835975B (zh) 2012-11-21
NL1026829C2 (nl) 2005-07-05
ATE484525T1 (de) 2010-10-15
MXPA06001634A (es) 2006-04-28
UA85058C2 (ru) 2008-12-25
EP1656391B1 (en) 2010-10-13
MA27988A1 (fr) 2006-07-03
OA13234A (en) 2006-12-13
TNSN06050A1 (fr) 2007-10-03
US7371378B2 (en) 2008-05-13
JP4638870B2 (ja) 2011-02-23
CR8233A (es) 2007-01-18
UY28464A1 (es) 2005-03-31
WO2005016967A2 (en) 2005-02-24
RS20060099A (en) 2008-08-07
US20050069539A1 (en) 2005-03-31
IL173273A (en) 2011-10-31
CL2004002035A1 (es) 2005-06-03
CA2535071A1 (en) 2005-02-24
EA200600234A1 (ru) 2006-08-25
PE20050339A1 (es) 2005-05-17
DK1656391T3 (da) 2011-01-03
BRPI0413466A (pt) 2006-10-17
AR045247A1 (es) 2005-10-19
PL1656391T3 (pl) 2011-03-31
ECSP066359A (es) 2006-10-31
US20080181891A1 (en) 2008-07-31
AP2006003510A0 (en) 2006-02-28
KR100825156B1 (ko) 2008-04-24
US7575746B2 (en) 2009-08-18
NO20060542L (no) 2006-05-03
ES2351395T3 (es) 2011-02-04
TWI294915B (en) 2008-03-21
PA8608801A1 (es) 2005-03-03
DE602004029581D1 (de) 2010-11-25
TW200516145A (en) 2005-05-16
ZA200601231B (en) 2007-05-30
PT1656391E (pt) 2010-12-06
CN1835975A (zh) 2006-09-20
GT200400158A (es) 2005-07-22
IL173273A0 (en) 2006-06-11
EP1656391A2 (en) 2006-05-17
KR20060035796A (ko) 2006-04-26
NL1026829A1 (nl) 2005-02-15
JP2007527705A (ja) 2007-10-04

Similar Documents

Publication Publication Date Title
IS8266A (is) Breytt mennsk IGF-1R mótefni
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
DK1599504T3 (da) Modificeret antistof
NO20044347L (no) Anti-alfavbeta6-antistoff
CY2016035I2 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DE602004022855D1 (de) Interleukin-10-antikörper
NO20071430L (no) Anti-OX4OL antistoffer
NO2016001I2 (no) Trastuzumab emtansin
PL2177537T3 (pl) Przeciwciała przeciw MadCAM
ATE549033T1 (de) Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
DE502004003292D1 (de) Flugzeug
EP1607081A4 (en) COSMETIC PREPARATION
EP1765396A4 (en) ANTIBODY
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
DE502004012209D1 (de) Einparkhilfe
DK1809660T3 (da) Thymus-specifikt protein
PT1678290T (pt) Resumo
EP1646401A4 (en) SPECIFIC HUMAN ANTIBODIES
DE602004023341D1 (de) Chronograph
NO20053512D0 (no) IL-8-liknende proteiner
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa
DK1494693T3 (da) Cripto-specifikke antistoffer
NO20052608D0 (no) Midkinlignende protein
DE602004012372D1 (de) Fahrradpedal
PT9865T (pt) Asa rotulo